Quoin Pharmaceuticals reported significant regulatory progress for QRX003, a treatment for Netherton Syndrome, including FDA Fast Track designation and positive feedback on Phase 3 trial design. The company aims to complete Phase 3 patient recruitment by the end of 2026 and potentially file for FDA approval in 2027. Additionally, Quoin is advancing its QRX009 topical rapamycin program with planned clinical studies for several rare diseases. Financially, Quoin holds $14 million in cash and expects to fund operations into 2027 despite a net loss of $5 million in Q1 2026.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
Lockheed Martin Ventures, the $1 billion venture capital arm of Lockheed Martin, is expanding into the UK and Europe with a new London office. It plans to invest at least $100 million in defense technology startups to strengthen transatlantic defense...
